Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Definium Therapeutics, Inc.

Healthcare US DFTX

36.545USD
12.06(49.29%)

Last update at 2026-06-22T15:11:00Z

Day Range

35.1339.16
LowHigh

52 Week Range

6.0326.25
LowHigh

Fundamentals

  • Previous Close 24.48
  • Market Cap2311.00M
  • Volume11398396
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-166.28200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -183.79300M -108.67900M -95.73200M -56.79600M -94.19300M
Minority interest - - - - -
Net income -183.79300M -108.67900M -95.73200M -56.79600M -93.03600M
Selling general administrative 48.64M 38.62M 41.74M 30.16M 59.06M
Selling and marketing expenses - - - - -
Gross profit - -0.52700M -3.16200M - -
Reconciled depreciation 0.00000M 0.53M 3.16M 3.18M 2.62M
Ebit - -106.39600M -95.73200M -66.33100M -93.85400M
Ebitda -178.31100M -105.86900M -92.57000M -63.15100M -91.23800M
Depreciation and amortization - 0.53M 3.16M 3.18M 2.62M
Non operating income net other - - - - -
Operating income -166.30900M -103.91600M -93.86600M -66.33100M -93.85400M
Other operating expenses 166.31M 103.92M 93.87M 66.33M 93.85M
Interest expense 5.48M 2.28M 0.92M 1.50M 0.36M
Tax provision - - - 0.00000M -1.15700M
Interest income 10.96M 11.56M 5.58M - -
Net interest income 5.48M 9.28M 4.66M 1.50M -0.35900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -1.15700M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 166.31M 103.39M 90.70M 66.33M 93.85M
Cost of revenue - 0.53M 3.16M - -
Total other income expense net -17.48400M -4.76300M -1.86600M 9.54M -0.33900M
Discontinued operations - - - - -
Net income from continuing ops -183.79300M -108.67900M -95.73200M -56.79600M -93.03600M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 440.10M 302.15M 124.54M 169.99M 164.00M
Intangible assets - - 0.53M 3.69M 6.87M
Earning assets - - - - -
Other current assets 7.73M 7.88M 4.17M 3.91M 3.68M
Total liab 107.77M 60.70M 46.41M 19.08M 12.34M
Total stockholder equity 332.33M 241.45M 78.13M 150.92M 151.66M
Deferred long term liab - - - - -
Other current liab 61.35M 36.84M 28.11M 15.71M 6.23M
Common stock - - - - -
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -582.67200M -398.87900M -290.20000M -194.46800M -137.67200M
Other liab - - - - -
Good will 19.92M 19.92M 19.92M 19.92M 19.92M
Other assets - - - - -
Cash 257.84M 273.74M 99.70M 142.14M 133.54M
Cash and equivalents - - - - -
Total current liabilities 66.70M 38.85M 32.25M 17.89M 10.41M
Current deferred revenue - - - - -
Net debt -257.83700M -251.88700M -85.57500M -142.07000M -133.53900M
Short term debt - - - 0.07M -
Short long term debt - - - - -
Short long term debt total - 21.85M 14.13M 0.07M -
Other stockholder equity 913.91M 639.51M 367.99M 344.76M 288.29M
Property plant equipment - - - - -
Total current assets 419.32M 281.62M 103.87M 146.06M 137.22M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments 153.76M 0.00000M - - -
Net receivables - - - - -
Long term debt 40.58M 21.85M 14.13M - -
Inventory - - - - -
Accounts payable 5.35M 2.01M 4.14M 2.11M 4.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.08M 0.82M 0.34M 0.63M 1.05M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.86M 0.61M 0.22M 0.33M -
Deferred long term asset charges - - - - -
Non current assets total 20.78M 20.53M 20.67M 23.94M 26.79M
Capital lease obligations - - - 0.07M 0.00000M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -151.60600M 0.00000M - - -
Change to liabilities - - - - -
Total cashflows from investing activities -151.60600M - - - -0.29700M
Net borrowings 20.00M 10.86M 21.68M 0.00000M -
Total cash from financing activities 267.27M 253.20M 21.85M 59.05M 98.82M
Change to operating activities - - - - -
Net income -183.79300M -108.67900M -95.73200M -56.79600M -93.03600M
Change in cash -15.90400M 174.04M -42.43800M 8.60M 53.45M
Begin period cash flow 273.74M 99.70M 142.14M 133.54M 80.09M
End period cash flow 257.84M 273.74M 99.70M 142.14M 133.54M
Total cash from operating activities -131.56000M -79.12900M -64.36500M -50.13900M -45.82400M
Issuance of capital stock 258.86M 250.00M 0.00000M 42.30M 81.92M
Depreciation 0.00000M 0.53M 3.16M 3.18M 2.62M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 267.27M -7.65900M 0.16M 16.75M 16.90M
Change to netincome - - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 9.44M -3.34400M 6.28M -3.78200M 1.88M
Stock based compensation 20.10M 16.91M 15.49M 13.71M 42.72M
Other non cash items 22.70M 15.45M 8.46M -6.44800M 1.16M
Free cash flow -131.56000M -79.12900M -64.36500M -50.13900M -45.82400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
DFTX
Definium Therapeutics, Inc.		 12.06 49.29% 36.55 - - - 6.95
NVO
Novo Nordisk A/S		 2.50 5.78% 45.69 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.55 1.23% 457.18 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.77 1.60% 600.17 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Definium Therapeutics, Inc.

One World Trade Center, New York, NY, United States, 10007

Key Executives

Name Title Year Born
Mr. Robert Barrow CEO & Director 1990
Mr. Mark R. Sullivan J.D. Chief Legal Officer & Corporate Secretary 1971
Dr. Daniel Rollings Karlin M.A., M.D. Chief Medical Officer 1981
Dr. Scott M. Freeman M.D. Co-Founder & Clinical Advisor 1957
Mr. Leonard Latchman Co-Founder NA
Ms. Brandi L. Roberts CPA, M.B.A. Chief Financial Officer 1974
Mr. Peter Mack Senior Vice President of Pharmaceutical Development & Operations NA
Ms. Gitanjali Jain Ogawa VP & Head of Investor Relations NA
Ms. Beth Calitri Vice President of Corporate Communications NA
Ms. Stephanie Fagan M.S. Chief Corporate Affairs Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions